Blog

Health Care Professionals’ Perspectives are Essential to Greater Biosimilar Adoption

Since the first biosimilar was approved in the U.S. in 2015, these life savings therapies have provided nearly $13 billion... Read more »
Congress considers BBB Drug pricing negotiation

Drug Price Negotiation Proposals Undermine Current Bipartisan Approaches to Lower Drug Spending

Congress is actively seeking to advance legislation to allow the Medicare program to “negotiate” the prices of brand drugs. However,... Read more »
The Federal Trade Commission

AAM Calls for Federal Trade Commission to Investigate PBM Business Practices

On May 23, 2022, the Association for Accessible Medicines and its Biosimilars Council urged the Federal Trade Commission (FTC) to... Read more »
Biosimilars Patient Resource Center

Everything You Need to Know About Biosimilars – All in One Place

Biosimilar medicines are revolutionary therapeutics that treat patients at a fraction of the cost of brand-name biologics. However, public awareness... Read more »

HHS OIG Report Demonstrates Need for Changes to Part D to Increase Biosimilar Use

Biosimilars provide more options for care at a lower cost for patients, but due to Medicare’s perverse incentives, many PBMs... Read more »
Biosimilars helping patients

Treating Ulcerative Colitis, and Enjoying a Slice or Two

Greg, 37, of Los Angeles, CA., spends most of his time hiking, running and lifting weights, but his greatest passion... Read more »
Biosimilars Helping patient

Singing, Dancing and Taking Care of Herself with Biosimilars

Eileen, 28, lives in New York City and is pursuing her dream of a career in musical theater. Her stage... Read more »
Biosimilar law policy

BsUFA Reauthorization and Modernization Is the Key to a Healthy Biosimilar Market

This year, Congress will consider legislation that codifies performance goals for the review of drug applications by the U.S. Food... Read more »

Access! 2022 Conference Recap

February 14-16, AAM and its Biosimilars Council welcomed attendees to Orlando, Florida for Access! 2022, the generics and biosimilars industry’s... Read more »
Biosimilars in 2022

Increase Patient Access to Biosimilars in 2022

Last year was full of exciting developments for patients who rely on biosimilars. Here’s a look at what we’re working... Read more »
Rheumatoid Arthritis awareness

Biosimilar Medicines Bring New Optimism on RA Awareness Day

On February 2 we mark Rheumatoid Arthritis (RA) Awareness Day and shine a light on the roughly 1.5 million Americans... Read more »

Proposed BBB Negotiation Framework Discourages Biosimilar Competition, Imposes Higher Costs on Commercially Insured Patients and Their Employers

This week, we learned that employers experienced a 6.3% jump in health benefit costs last year.1Findings such as these, paired with... Read more »

The Evidence Is Clear: Biosimilar Competition Will Achieve More Savings for Patients Than Build Back Better’s Negotiations

The biosimilars industry is proving that market competition works to drive down drug costs and increase patient access to medicines.... Read more »

Patients Increasingly Rely on Oncology Biosimilar Medicines

Biosimilar medicines are increasingly becoming an essential fixture in health care, reducing prices and increasing patient access. This is especially... Read more »

AAM Annual Savings Report – Biosimilars and Bending the Cost Curve

Since the enactment of the Biologics Price Competition and Innovation Act in 2010, patients with complex disease have been eager... Read more »
patient access to biosimilars

Increase Patient Access to Lower-Cost Biosimilar Medicines

Since the biosimilars pathway (BPCIA) was established in 2010, 30* biosimilars have been approved. However, due to significant barriers to... Read more »
The Biosimilars Council - Doctors with hands in the middle

Organizations Thank Rep. Schrader, Kinzinger for Introducing the BIOSIM Act

Today, a group of organizations representing patients, employers, taxpayers, providers, communities of color and consumer groups sent a letter thanking... Read more »

Increasing Provider Reimbursement for Biosimilars Will Lead to Greater Adoption

Biosimilar competition has the potential to provide greater access to important treatments for America’s patients and cost savings for the… Read more »

Biosimilar Medicines Equal More Accessible Care for America’s Patients

In recent years, significant attention has been given to the advent of biosimilars, a new class of medicines approved by... Read more »

IQVIA Report Highlights Options to Boost U.S. Provider Use of Biosimilars

Biosimilars were first introduced in the United States about five years ago to treat patients with various medical conditions including... Read more »

Access! 2021 Is Coming. Here’s What You Need to Know

Access!, AAM’s annual meeting for the generics and biosimilars industry, brings policymakers, influential speakers and industry leaders together to share... Read more »

New Analyses Point to Opportunities to Increase Savings from Biosimilar Adoption

Since the first biosimilar launched in the U.S. market five years ago, the U.S. Food and Drug Administration (FDA) has... Read more »
world cancer day

Cancer Costs and Options for Care in the United States

In 2020, cancer claimed the lives of 600,000 Americans. According to the American Cancer Society (ACS CAN), there are approximately... Read more »
biosimilars facts

Biosimilars Facts

Biosimilar medicines are safe, effective alternative versions of existing brand biologic medicines (known as “reference products”) with scientifically comparable quality, safety... Read more »
global biosimilars week

Biosimilars Council Joins IGBA in Celebrating Global Biosimilars Week

Biosimilars are critical to the discussion around health care and its rising costs, as they have the potential to save... Read more »
United States Courthouse Close Up view

Affordable Care Act and the Future of Biosimilars

Today, the U.S. Supreme Court will hear arguments on the constitutionality of the Affordable Care Act (ACA). Although the case... Read more »
ten years of biosimilars

Ten Years of Biosimilars in the U.S.

The Biologics Price Competition and Innovation Act of 2010 (BPCIA) provides a framework for biosimilars approval, adoption and access in... Read more »
increasing access to biosimilars act

Patent Abuse Blocks Patient Access to Needed Biosimilars

Biosimilar developers must combat several obstacles in bringing a product to market, including patent litigations like this, while brand companies... Read more »
Biosimilars News May 2020

How a Biosimilar is Developed

Before biologic drugs are ready to be used by patients, scientists and providers spend years developing, researching, and testing them... Read more »
biosimilars news january 2020

Advocacy for Patient Access to Biosimilars

According to a report on biosimilars cost savings in the U.S., biosimilars could lead to over $54 billion in savings... Read more »
Approved Biosimilars

What are biosimilars?

Biosimilars are biologic medicines that are highly similar to a previously approved reference biologic currently on the market. But what does that short definition of a biosimilar actually mean?... Read more »
Resources

ERIC Launches Initiative to Understand Biosimilars Potential to Lower Health Care Costs

More than 180 million Americans receive health care benefits through their employer, with large employers paying more than 80 percent... Read more »

Biosimilars Study Shows Massive State Savings Potential

According to a study released by Pacific Research Institute, biosimilars have the potential to bring significant savings to both state... Read more »
biosimilars year in review

Biosimilars Council 2019 Year in Review

2019 was a whirlwind year for biosimilars, highlighted by a record 10 U.S. Food and Drug Administration (FDA) approvals and... Read more »

GRx+Biosims 2019 Conference: Advancing Biosimilars Access

Earlier this month the Association for Accessible Medicines (AAM) and its Biosimilars Council hosted the second annual GRx+Biosims Conference for... Read more »

FDA Releases New Biosimilars Education Materials for Patients

When it comes to ensuring medicines  — including biosimilars — are safe and effective for patients, the FDA remains the… Read more »

Biosimilar Benefits to Patients, Health Care Professionals and the U.S. Market

Dr. Sameer Awsare, Internal Medicine Physician and Associate Executive Director at Kaiser Permanente Medical Group, sat down with the Biosimilars… Read more »

The Importance of Naming for Market Adoption of Biosimilars

Hillel Cohen Executive Director, Scientific Affairs, Sandoz, Inc. Written by Hillel P. Cohen Biosimilars are a competitive, effective alternative for... Read more »

Chip Davis: “The Biosimilars Wave is Coming. Are Pharmacists Prepared?”

In a recent for Drug Store News, Chip Davis, President and CEO for the Association of Accessible Medicines, discusses the... Read more »

Abandoning Biosimilars Leaves Savings on the Table and Patients in the Lurch

A recent series in Health Affairs questioned whether competition from biosimilar medicines is a viable path to providing relief from… Read more »

Bipartisan Legislation Targets Patent Thickets, Supports Biosimilars Uptake

The Biologic Patent Transparency Act, introduced in March and sponsored by Senators Susan Collins (R-ME) and Tim Kaine (D-VA), would... Read more »
Biosimilars Council Recap of Access! 2019

Biosimilars Council Recap of Access! 2019

Earlier this month in New Orleans, the Association for Accessible Medicines and its Biosimilars Council hosted our annual Access! Conference. Attendees from... Read more »
Brand Efforts Seek to Limit Patient Access to Biosimilars

Brand Efforts Seek to Limit Patient Access to Biosimilars

Actions by branded companies to undermine proven safe, effective biosimilars hurt patients. U.S. Food & Drug Administration Commissioner Scott Gottlieb... Read more »
Biosimilars Council - Biosimilars Approvals Speeding Up

FDA Approval of Biosimilars Picking Up Pace

On Friday, December 14, the U.S. Food and Drug Administration (FDA) announced its sixteenth biosimilar approval for biosimilar trastuzumab, a drug used in... Read more »
Biosimilars Education Course for Clinicians

New Resource: Biosimilars Education Course for Clinicians

The American Society of Hematology (ASH) has added to its eLearning platform a new educational course titled “Biosimilars: A New Era of Hematology/Oncology... Read more »
Stairs and columns in front of the United States Supreme Court in Washington DC.

Taking Steps to Increase Patient Access to Life Altering Biosimilar Medicines

The burden of high prescription medicine costs for America’s patients continues to drive much of the national health care conversation and... Read more »
Biosimilars Council - Pass the CREATES Act

Cleveland Clinic Chief Pharmacy Officer: Time to Pass the CREATES Act

Scott Knoer, M.S., Pharm.D, serves as Chief Pharmacy Officer for the Cleveland Clinic, one of the largest hospitals nationwide. In... Read more »
Frontiers for Public Health Study - Biologics

New Study: Pharmacist Involvement Key to Reducing Cost of Biologics

A recent Italian study published in Frontiers in Public Health examined the effect of including a pharmacist in the Department of Abdominal... Read more »
APhA - Biosimilars Council - Biosimilars Basics for Patients

Pharmacists: On the Front Lines of Biosimilar Education

Pharmacists are among the most trusted health care professionals in America. Millions of patients rely on their pharmacist for guidance... Read more »
Biosimilars Council - IQVIA Report - Advancing Biosimilar Sustainability in Europe

IQVIA Releases Report Detailing Sustainability of Biosimilars in European Markets

IQVIA, a leading healthcare research company, recently released a new report, “Advancing Biosimilar Sustainability in Europe,” which examines the status of biosimilars... Read more »
Biosimilars Council - AAM This Month - August - Pills Background

AAM This Month – August

The Biosimilars Council's parent organization, the Association for Accessible Medicines (AAM), is active in promoting education around a variety of... Read more »
Biosimilars Council - Doctor Writing Prescription

Health Organizations Pen Letter to FDA Encouraging Action on Interchangeability Guidance

Seventeen stakeholder groups representing a variety of healthcare industry’s sent a letter to FDA, urging greater clarity on interchangeability guidance... Read more »
Biosimilars Council - Doctors Standing Together

Biosimilars Council Joins Other North American Generic Drugmakers in Rejection of New Exclusivity Period for Biologics

This week, the United States announced that it has reached a preliminary agreement with our North American counterparts, Canada and... Read more »
Biosimilars Council - Doctor Shaking Hand of Patient

New Council Partnerships Boost Patient Understanding of Biosimilars’ Benefits

This week, the United States announced that it has reached a preliminary agreement with our North American counterparts, Canada and... Read more »
Biosimilars Council - Large Meeting with Conference Attendees

The Biosimilars Council Congressional Briefing: Five Takeaways

Last Friday, The Biosimilars Council hosted a congressional briefing titled “Biosimilars: The Challenges and Promise of Patient Access.” AAM’s Craig Burton moderated a discussion... Read more »
Biosimilars Council - Microscope Up Close

Misinformation on Biosimilars Undermines Patient and Prescriber Confidence

Science, Data and FDA Support the Safety and Efficacy of Biosimilars for Patients As the biosimilars market begins to expand... Read more »
Biosimilars Council - Bottles being filled

The Naming of Biosimilar Medicines Worldwide Should Promote Patient Safety and Prescriber Confidence

In response to the growing number of biosimilar approvals and increased acceptance of their safety and efficacy a number of... Read more »
Biosimilars Council - Pharmacists looking at Computer

Why Increasing Patient Awareness of Biosimilars Is Important

Today’s healthcare arsenal includes biological products, or biologics, that are used in the treatment, prevention or diagnosis of diseases and... Read more »
Biosimilars Council - FDA Website Screenshot

FDA’s Steps to Improve Biosimilars Access in 2017 and Beyond

2017 was a watershed year for patients seeking affordable alternatives to expensive biologic medicines . The number of FDA-approved biosimilars more... Read more »
Biosimilars Council - Doctor with Child Patient

Why Biosimilars Are Important for Patients

Since their first use in the 1980s, biologic medicines have grown to become an indispensable tool in modern medicine. Advancements... Read more »
The Biosimilars Council - Doctor discussing with happy patient

A Watershed Year for Biosimilars in the U.S.

For anyone following the nascent biosimilars market in the U.S., 2017 has been a busy year: the Centers for Medicare... Read more »
The Biosimilars Council - Doctor taking patient blood pressure

Mind the Gap: Realizing Savings and Increasing Patient Access to Biosimilars in Medicare Part D

Biosimilars hold great promise for patients seeking access to more affordable versions of critical medicines, but also for a health care system facing unsustainable, increasing costs. One of the most immediate challenges to biosimilars uptake in the United State sis the lack of […]

The Biosimilars Council - Doctors Discussing in a Circle

Forging a Path: How We Are Leading on Access to Biosimilars

In the fast-paced world of health care, the role of the patient continues to evolve from passive to active. One of the most pressing issues patients face is the cost of their medications, which can serve as a significant barrier to access, especially for expensive brand-name biologic medicines[…]

The Biosimilars Council - Doctors Applauding

Leading on Biosimilars: 2017 AAM Biosimilars Council Conference Preview

Join us as we examine the promise of biosimilars in the United States and discuss how best to ensure patient... Read more »
The Biosimilars Council - Doctor with Stethoscope and pens

New Study: Biosimilars Earn the Trust of Health Insurers

This week, Avalere Health published new research that found 81% of health insurers are covering at least one of the... Read more »

Event Recap: The Next Drugs: The Future for Biosimilars

On June 7th, The Atlantic presented “The Next Drugs: The Future for Biosimilars – An Atlantic Policy Update on Biosimilars” at the Newseum in Washington, D.C. The third in a series of Atlantic biosimilars briefings underwritten by The Biosimilars Council […]

Biosimilars Council & The Atlantic: The Next Drugs: The Future for Biosimilars

Biosimilars not only have the unique ability to provide patients with much-needed access to lower-cost complex therapies, but also offer the potential for billions in patient, insurer and health system savings. But there are barriers […]

The Biosimilars Council - Table with Phones from Overhead

The Next Drugs: An Atlantic Policy Update on Biosimilars

Working in coordination with The Atlantic, an award-winning publication that covers politics, business, and technology, The Biosimilars Council will continue its efforts to educate consumers about biosimilars by bringing together key stakeholders to debate the state and future of biosimilars […]

Doctor forward with child patient behind

Supreme Court Hears Biosimilars Patent Case

The country has undergone a great deal of change from December to today – but one thing that has not changed is that Americans want action to bring down the price of prescription drugs. A recent Kaiser Health Tracking Poll showed that over 60% of Americans believe lowering the cost of […]

Recapping: The Future For Biosimilars (an Atlantic policy briefing)

On March 15th, The Atlantic presented “The Next Drugs: The Future for Biosimilars – An Atlantic Policy Briefing” at the Newseum in Washington, D.C. Underwritten by The Biosimilars Council, more than 100 influencers from across the […]

Recent Tweets

Unable to load Tweets